GB0207449D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
GB0207449D0
GB0207449D0 GBGB0207449.0A GB0207449A GB0207449D0 GB 0207449 D0 GB0207449 D0 GB 0207449D0 GB 0207449 A GB0207449 A GB 0207449A GB 0207449 D0 GB0207449 D0 GB 0207449D0
Authority
GB
United Kingdom
Prior art keywords
novel compounds
novel
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0207449.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GBGB0207449.0A priority Critical patent/GB0207449D0/en
Publication of GB0207449D0 publication Critical patent/GB0207449D0/en
Priority to TW092106782A priority patent/TW200400823A/zh
Priority to CA002479910A priority patent/CA2479910A1/en
Priority to CNA038068656A priority patent/CN1642553A/zh
Priority to DE60330952T priority patent/DE60330952D1/de
Priority to BR0308719-0A priority patent/BR0308719A/pt
Priority to AU2003216905A priority patent/AU2003216905A1/en
Priority to RU2004126145/04A priority patent/RU2004126145A/ru
Priority to PL03372930A priority patent/PL372930A1/xx
Priority to IL16364803A priority patent/IL163648A0/xx
Priority to MXPA04009458A priority patent/MXPA04009458A/es
Priority to ARP030101090A priority patent/AR039177A1/es
Priority to ES03712117T priority patent/ES2339436T3/es
Priority to EP03712117A priority patent/EP1487453B1/en
Priority to US10/509,417 priority patent/US20060058299A1/en
Priority to AT03712117T priority patent/ATE454892T1/de
Priority to PCT/EP2003/003339 priority patent/WO2003082291A1/en
Priority to JP2003579828A priority patent/JP4490110B2/ja
Priority to KR10-2004-7015447A priority patent/KR20040095347A/ko
Priority to IS7415A priority patent/IS7415A/is
Priority to ZA200406990A priority patent/ZA200406990B/en
Priority to NO20044098A priority patent/NO20044098L/no
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
GBGB0207449.0A 2002-03-28 2002-03-28 Novel compounds Ceased GB0207449D0 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
GBGB0207449.0A GB0207449D0 (en) 2002-03-28 2002-03-28 Novel compounds
TW092106782A TW200400823A (en) 2002-03-28 2003-03-26 Novel compounds
KR10-2004-7015447A KR20040095347A (ko) 2002-03-28 2003-03-27 염증 질환을 치료하기 위한 ｃｃｒ３ 길항제로서의ｎ-｛[(2ｓ)-4-(3,4-디플루오로벤질)모르폴린-2-일]메틸｝-2-｛3-[(메틸설포닐)아미노]페닐｝아세트아미드
MXPA04009458A MXPA04009458A (es) 2002-03-28 2003-03-27 N-[¦(2s)-4 -(3, 4-difluorobencil) morfolin- 2il!metil] -2-[3- ¦(metilsulfonil) amino!fenil] acetamida como antagonistas cc3 para el tratamiento de condiciones inflamatorias.
EP03712117A EP1487453B1 (en) 2002-03-28 2003-03-27 N- ¬(2s)-4-(3,4-difluorobenzyl)morpholin-2-yl methyl -2- 3-¬(methylsulphonyl)amino phenyl acetamide as ccr3 antagonist for the treatment of inflammatory conditions
DE60330952T DE60330952D1 (de) 2002-03-28 2003-03-27 N- i(2S)-4-(3,4-DIFLUOROBENZYL)MORPHOLIN-2-YL METHYL -2- 3-i(METHYLSULPHONYL)AMINO PHENYL ACETAMID ALS CCR3 ANTAGONIST FÜR DIE BEHANDLUNG VON ENTZÜNDLICHEN ERKRANKUNGEN
BR0308719-0A BR0308719A (pt) 2002-03-28 2003-03-27 Composto e sais e solvatos deste, processo para a preparação do mesmo, método de tratamento de um paciente humano ou animal que sofre ou é suscetìvel a uma condição inflamatória, e, composição farmacêutica
AU2003216905A AU2003216905A1 (en) 2002-03-28 2003-03-27 N-{´(2S)-4-(3,4-difluorobenzyl) morpholin-2yl!methyl} -2-{3-' (methylsulphonyl)amino!phenyl}acetamide as CCR3 antagonist for the treatment of inflammatory conditions
RU2004126145/04A RU2004126145A (ru) 2002-03-28 2003-03-27 N-{[(2s)-4-(3,4-дифторбензил)морфолин-2ил]-метил}-2-{3- [(метилсульфонил)амино]фени л}ацетамид в качестве антагониста ccr-3 для лечения восполительных состояний
PL03372930A PL372930A1 (en) 2002-03-28 2003-03-27 N-{[(2s)-4- (3,4-difluorobenzyl) morpholin-2yl] methyl} -2-{3-[(methylsulphonyl) amino] phenyl} acetamide as ccr3 antagonist for the treatment of inflammatory conditions
IL16364803A IL163648A0 (en) 2002-03-28 2003-03-27 B-ä'(2S)-4-(3,4-difluorobenzyl)morpholin-2-ylmethylü-2-ä3-'(methylsulphonyl)aminophenylüacetamide asccr3 antagonist
CA002479910A CA2479910A1 (en) 2002-03-28 2003-03-27 N-{ '(2s) -4- (3, 4-difluorobenzyl) morpholin-2yl!methyl} -2-{3-' (methylsulphonyl) amino! phenyl}acetamide as ccr3 antagonist for the treatment of inflammatory conditions
ARP030101090A AR039177A1 (es) 2002-03-28 2003-03-27 Derivados de morfolina, antagonistas de ccr3.
ES03712117T ES2339436T3 (es) 2002-03-28 2003-03-27 N-((2s)-4-(3,4-difluorobencil)morfolin-2-ilmetil)2-3-'(metilsulfonil)aminofenil) acetamida como antagonista ccr3 para el tratamiento de condiciones inflamatorias.
CNA038068656A CN1642553A (zh) 2002-03-28 2003-03-27 N －{ [ ( 2 s ) － 4 － ( 3 , 4－二氟苄基 )吗啉 － 2 －基}甲基} － 2 －{ 3 － [ (甲基磺酰基 )氨基 ]苯基}乙酰胺作为ccr3拮抗剂用于治疗炎症
US10/509,417 US20060058299A1 (en) 2002-03-28 2003-03-27 N-2s-4-3,4-difluorobenzyl morpholin-2yl methyl -2-(3-methylsulphonyl amino!phenyl acetamide as ccr3 antagonist for the treatment of inflammatory conditions
AT03712117T ATE454892T1 (de) 2002-03-28 2003-03-27 N- (2s)-4-(3,4-difluorobenzyl)morpholin-2-yl methyl -2- 3- (methylsulphonyl)amino phenyl acetamid als ccr3 antagonist für die behandlung von entzündlichen erkrankungen
PCT/EP2003/003339 WO2003082291A1 (en) 2002-03-28 2003-03-27 N-{´ (2s) -4- (3, 4-difluorobenzyl) morpholin-2yl!methyl} -2-{3-' (methylsulphonyl) amino! phenyl}acetamide as ccr3 antagonist for the treatment of inflammatory conditions
JP2003579828A JP4490110B2 (ja) 2002-03-28 2003-03-27 炎症性症状の治療のためのｃｃｒ３拮抗薬としての、ｎ−｛［（２ｓ）−４−（３，４−ジフルオロベンジル）モルホリン−２−イル］メチル｝−２−｛３−［（メチルスルホニル）アミノ］フェニル｝アセトアミド
IS7415A IS7415A (is) 2002-03-28 2004-08-19 N-{'(2S)-4-(3,4-díflúrbensýl)morfólín-2ýl!metýl}-2-{3-'(metýlsúlfónýl)amínó!fenýl} asetamíð sem CCR3 mótlyf fyrir meðhöndlun bólgusjúkdóma
ZA200406990A ZA200406990B (en) 2002-03-28 2004-09-01 N-äÄ(2S)-4-(3,4-Difluorobenzyl)morpholin-2ylÜmethylü-2-ä3-Ämethylsulphonyl)aminoüphenylüacetamide asCCR3 antagonist for the treatment of inflammatory conditions.
NO20044098A NO20044098L (no) 2002-03-28 2004-09-27 Nye forbindelser

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0207449.0A GB0207449D0 (en) 2002-03-28 2002-03-28 Novel compounds

Publications (1)

Publication Number Publication Date
GB0207449D0 true GB0207449D0 (en) 2002-05-08

Family

ID=9933998

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0207449.0A Ceased GB0207449D0 (en) 2002-03-28 2002-03-28 Novel compounds

Country Status (22)

Country Link
US (1) US20060058299A1 (https=)
EP (1) EP1487453B1 (https=)
JP (1) JP4490110B2 (https=)
KR (1) KR20040095347A (https=)
CN (1) CN1642553A (https=)
AR (1) AR039177A1 (https=)
AT (1) ATE454892T1 (https=)
AU (1) AU2003216905A1 (https=)
BR (1) BR0308719A (https=)
CA (1) CA2479910A1 (https=)
DE (1) DE60330952D1 (https=)
ES (1) ES2339436T3 (https=)
GB (1) GB0207449D0 (https=)
IL (1) IL163648A0 (https=)
IS (1) IS7415A (https=)
MX (1) MXPA04009458A (https=)
NO (1) NO20044098L (https=)
PL (1) PL372930A1 (https=)
RU (1) RU2004126145A (https=)
TW (1) TW200400823A (https=)
WO (1) WO2003082291A1 (https=)
ZA (1) ZA200406990B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003275257A1 (en) 2002-09-26 2004-04-19 Bristol-Myers Squibb Company N-substituted heterocyclic amines as modulators of chemokine receptor activity
EP1919884A1 (en) * 2005-07-21 2008-05-14 AstraZeneca AB N-benzyl-morpholine derivatives as modulators of the chemokine receptor
AU2006293635A1 (en) * 2005-09-22 2007-03-29 Sanofi-Aventis Amino-alkyl-amide derivatives as CCR3 receptor liquids
HUP0500877A2 (en) * 2005-09-22 2007-05-29 Sanofi Aventis Amide derivatives as ccr3 receptor ligands, process for producing them, pharmaceutical compositions containing them and their use and intermediates
HUP0500886A2 (en) * 2005-09-23 2007-05-29 Sanofi Aventis Amide derivatives as ccr3 receptor ligands, process for producing them, pharmaceutical compositions containing them and their use
HUP0800478A2 (en) * 2008-07-31 2010-03-01 Sanofi Aventis Substituted pyrrolidinyl-[1,3]thiazolo[4,5-b]pyridin derivatives as ccr3 receptor ligands
RU2014126070A (ru) * 2011-12-01 2016-01-27 Глэксо Груп Лимитед Способы лечения и предотвращения глазных заболеваний

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS562929A (en) * 1979-06-21 1981-01-13 Sumitomo Chem Co Ltd Preparation of optically active cyclopentenolone
US4870074A (en) * 1986-04-30 1989-09-26 Dainippon Pharmaceutical Co., Ltd. Substituted benzamide derivatives, for enhancing gastrointestinal motility
JPH01117882A (ja) * 1987-10-30 1989-05-10 Dainippon Pharmaceut Co Ltd 複素環式カルボン酸アミド誘導体
JPH03291274A (ja) * 1990-04-09 1991-12-20 Yoshitomi Pharmaceut Ind Ltd アミノアルキルモルホリン誘導体の製造法
JPH04270272A (ja) * 1991-02-25 1992-09-25 Yoshitomi Pharmaceut Ind Ltd アミノアルキルモルホリン誘導体の製造法
TW223629B (https=) * 1992-03-06 1994-05-11 Hoffmann La Roche
US5219856A (en) * 1992-04-06 1993-06-15 E. I. Du Pont De Nemours And Company Angiotensin-II receptor blocking, heterocycle substituted imidazoles
US6031097A (en) * 1997-10-27 2000-02-29 Neurogen Corporation 1-(N-(arylalkylaminoalkyl) aminoisoquinolines; a new class of dopamine receptor subtype specific ligands
AU2056800A (en) * 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company Heterocyclic piperidines as modulators of chemokine receptor activity
JP4717306B2 (ja) * 1999-09-14 2011-07-06 アベンティスユービー・セカンド・インコーポレイテッド Ｄ４拮抗剤として有用なチエノイソキサゾールフェノキシ非置換エチルおよびプロピル誘導体
IL155093A0 (en) * 2000-09-29 2003-10-31 Glaxo Group Ltd Morpholin-acetamide derivatives for the treatment on inflammatory diseases
IL155092A0 (en) * 2000-09-29 2003-10-31 Glaxo Group Ltd Compounds useful in the treatment of inflammatory diseases

Also Published As

Publication number Publication date
TW200400823A (en) 2004-01-16
AU2003216905A1 (en) 2003-10-13
RU2004126145A (ru) 2005-06-27
MXPA04009458A (es) 2005-07-27
DE60330952D1 (de) 2010-03-04
CN1642553A (zh) 2005-07-20
ES2339436T3 (es) 2010-05-20
PL372930A1 (en) 2005-08-08
JP2005525390A (ja) 2005-08-25
AR039177A1 (es) 2005-02-09
EP1487453A1 (en) 2004-12-22
CA2479910A1 (en) 2003-10-09
BR0308719A (pt) 2005-01-04
EP1487453B1 (en) 2010-01-13
JP4490110B2 (ja) 2010-06-23
IS7415A (is) 2004-08-19
WO2003082291A1 (en) 2003-10-09
ZA200406990B (en) 2005-11-08
IL163648A0 (en) 2005-12-18
ATE454892T1 (de) 2010-01-15
KR20040095347A (ko) 2004-11-12
US20060058299A1 (en) 2006-03-16
NO20044098L (no) 2004-10-04

Similar Documents

Publication Publication Date Title
GB0202216D0 (en) Novel compounds
GB0205256D0 (en) Novel compounds
GB0202679D0 (en) Novel compounds
GB0206723D0 (en) Novel compounds
GB0207249D0 (en) Novel compounds
GB0207246D0 (en) Novel compounds
GB0203299D0 (en) Novel compounds
GB0207449D0 (en) Novel compounds
GB0204252D0 (en) Novel compounds
GB0203437D0 (en) Novel compounds
GB0204255D0 (en) Novel compounds
GB0201231D0 (en) Novel compounds
GB0201357D0 (en) Novel compounds
GB0202140D0 (en) Novel compounds
GB0202141D0 (en) Novel compounds
GB0202217D0 (en) Novel compounds
GB0202219D0 (en) Novel compounds
GB0202442D0 (en) Novel compounds
GB0202636D0 (en) Novel compounds
GB0202637D0 (en) Novel compounds
GB0203300D0 (en) Novel compounds
GB0203301D0 (en) Novel compounds
GB0203363D0 (en) Novel compounds
GB0203369D0 (en) Novel compounds
GB0200787D0 (en) Novel compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)